Prediction of Absolute and Relative Benefit of Chemotherapy
Prediction of chemotherapy benefit was validated in a large comparative analysis with 3,746 pre- and postmenopausal patients with ER+, HER2- breast cancer. 2,630 patients were treated with 5 years of endocrine therapy alone (ET) and 1,116 patients were treated with endocrine plus chemotherapy (ET+C) with current (taxane and/or anthracycline-containing) treatment regimens. Primary endpoint was distant recurrence-free interval.
Patient distribution in the comparative analysis
The study indicates that EndoPredict is significantly predictive of chemotherapy benefit. Women with a high EPclin Risk Score (>3.3) and who received ET+C had a statistically significantly lower 10 year recurrence risk than those on ET alone. There was no statistically significant differences between ET+C and ET for patients with low EPclin Risk Scores (test for interaction: p=0.02). These women are unlikely to benefit from adjuvant chemotherapy.
EndoPredict Predicts The Individual Chemotherapy Benefit For Each Patient
10 year risk by EPclin Risk Score for endocrine treatment (ET) vs. endocrine treatment plus chemotherapy (ET+C)
Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019;176:377-386